• Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

  NCT03310008

  Unknown statusInterventionalPhase 1Updated Jun 16, 2020
• Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

  NCT03370198

  TerminatedInterventionalPhase 1Updated Feb 28, 2024
• DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

  NCT03466320

  CompletedInterventionalPhase 1Phase 2Updated May 4, 2021
• EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2

  NCT03612739

  WithdrawnInterventionalPhase 1Updated Oct 29, 2019
• A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

  NCT02869295

  CompletedInterventionalPhase 1Phase 2Updated Jul 29, 2021
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

  NCT02983045

  CompletedInterventionalPhase 1Phase 2Updated Mar 13, 2023

ClinicalTrials.gov ID

NCT03018405

Lead Sponsor

Celyad Oncology SAINDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

146Estimated

Last Update Posted

Sep 19, 2019Actual

Start Date

Dec 2016

Primary Completion Date

May 2021Estimated

Completion Date

Aug 2021Estimated

Official Title

A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)

Brief Summary

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).

Detailed Description

This open-label Phase I study aims at assessing the safety and clinical activity of the NKR-2 treatment administered 3 times with a 2-week interval between each administration in different tumor types. In absence of progressive disease at the first tumor assessment following NKR-2 administratio, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval. The study will contain two consecutive segments: a Phase I dose escalation and a Phase I expansion segment.

The Phase I dose escalation segment will include 2 arms, one in solid tumors and one in hematological tumors. The dose escalation design will include 3 dose levels: The dose escalation phase will consist of 3 cohorts (Cohorts 1-3) for the solid tumors, and 3 cohorts (Cohorts 4-6) for the hematological tumors; with each set of 3 cohorts receiving escalating doses of the NKR-2 therapy.

Two additional cohorts will be added in each dose escalation arm with the aim to provide a more intense treatment during the induction treatment. These additional cohorts in both the solid arm (cohort 8-9 - only in CRC) and in the hematological arm of the study (cohort 10-11 - only in AML/MDS) will therefore evaluate a tighter schedule of NKR-2 injections with the three first injections within the induction cycle separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections. These cohorts will each enroll 3 patients in case of no DLT. Based on safety and early clinical data from these cohorts, the specific schedule of cohorts 8-11 might be selected for the expansion.

• Acute Myeloid Leukemia/Myelodysplastic Syndrome
• Multiple Myeloma (MM)

• NKR-2 cells

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Main inclusion criteria are:

• Men or women ≥ 18 years old at the time of signing the ICF,
• Patient with a CRC, epithelial ovarian cell or fallopian tube carcinoma, urothelial carcinoma, TNBC, pancreatic cancer, AML/MDS or MM,
• Disease must be measurable according to the corresponding guidelines,
• Patient with an ECOG performance status 0 or 1, and AML patients with anemia resulting in an ECOG performance status of 2,
• Patient with adequate bone marrow reserve, hepatic and renal functions.
• Patients must have sufficient pulmonary functions with a Forced Expiratory Volume in the first second (FEV-1)/Forced Vital Capacity (FVC) ≥ 0.7 with FEV-1 ≥ 50% predicted.

Main exclusion criteria are:

• Patient with a tumor metastasis in the central nervous system,
• Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis (except hydroxyurea for AML patients),
• Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration (except hydroxyurea for AML patients),
• Patient is under systemic immunosuppressive drugs, unless specific cases authorized per protocol,
• Patients who have received other cell therapies,
• Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration.
• Patient cannot present with history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease (COPD).

Detailed disease specific criteria exist and can be discussed with contacts listed below.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Celyad Oncology SAINDUSTRY

anne.moxhon@uclouvain.be+32 2 764.42.17

michel.dubuisson@bordet.be+32 (0) 2 541 31 79

jonas.segaert@uzgent.be32 (0)9 332 4912